|1.||Purohit, A: 2 articles (10/2000 - 02/2000)|
|2.||Reed, M J: 2 articles (10/2000 - 02/2000)|
|3.||Hu, Liming: 1 article (02/2015)|
|4.||Lv, Wenping: 1 article (02/2015)|
|5.||Tao, Guanjun: 1 article (02/2015)|
|6.||Wang, Hongxin: 1 article (02/2015)|
|7.||Ma, Chaoyang: 1 article (02/2015)|
|8.||Rangiah, Kannan: 1 article (05/2011)|
|9.||Ciccimaro, Eugene: 1 article (05/2011)|
|10.||Blair, Ian A: 1 article (05/2011)|
|2.||Breast Neoplasms (Breast Cancer)
07/01/2005 - "In comparison, the T-47D, MCF-7, and MDA-MB-435s human breast cancer cells, which were highly sensitive to 2-MeO-E2, had very low or undetectable catalytic activity for the conversion of 2-MeO-E2 to 2-methoxyestrone. "
04/20/2004 - "Sulfamoylation of 2-methoxyestrone (2-MeOE1) was shown previously to enhance its potency as an anti-proliferative agent against breast cancer cells. "
10/01/2000 - "We demonstrated previously that the sulfamoylated estrone derivative 2-methoxyestrone-3-O-sulfamate (2-MeOEMATE) induced G2-M cell cycle arrest and modest levels of apoptosis in breast cancer cells in vitro, whereas the parent estrone derivative, 2-methoxyestrone, did not. "
02/25/2000 - "Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate."
02/25/2000 - "In the present investigation we have examined the ability of 2-methoxyestrone (2-MeOE1), 2-methoxyestradiol (2-MeOE2), 2-methoxyestrone-3-O-sulfamate (2-MeOEMATE), and a number of related compounds, to inhibit 2-deoxy-D-[1-(3)H]-glucose uptake in MCF-7 breast cancer cells. "
02/01/2015 - "Eleven urinary metabolites contributing to the differentiation were identified as anti-fatigue biomarkers: N-acetylserotonin, 2-Methoxyestrone 3-glucuronide, Taurine, Melatonin, Sorbitol, Geranyl diphosphate, Z-nucleotide, Cortisone, Dihydrocortisol, Sebacic acid, Pregnenolone sulfate. "
|2.||Biological Markers (Surrogate Marker)
|7.||Deoxyglucose (2 Deoxy D glucose)
|10.||AICA ribonucleotide (CAIR)